Cite
Kalpakoff M, Hund S, Musser J, et al. Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx. Appl Immunohistochem Mol Morphol. 2021;29(9):667-673doi: 10.1097/PAI.0000000000000941.
Kalpakoff, M., Hund, S., Musser, J., Roach, C., Apostolaki, A., Vilardo, M., Peltz, L., Watts, B., LaPlaca, C., Tabuena-Frolli, S., DiMaio, M. A., Welcher, R., & Kulangara, K. (2021). Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx. Applied immunohistochemistry & molecular morphology : AIMM, 29(9), 667-673. https://doi.org/10.1097/PAI.0000000000000941
Kalpakoff, Megan, et al. "Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx." Applied immunohistochemistry & molecular morphology : AIMM vol. 29,9 (2021): 667-673. doi: https://doi.org/10.1097/PAI.0000000000000941
Kalpakoff M, Hund S, Musser J, Roach C, Apostolaki A, Vilardo M, Peltz L, Watts B, LaPlaca C, Tabuena-Frolli S, DiMaio MA, Welcher R, Kulangara K. Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx. Appl Immunohistochem Mol Morphol. 2021 Oct 01;29(9):667-673. doi: 10.1097/PAI.0000000000000941. PMID: 33973887; PMCID: PMC8505133.
Copy
Download .nbib